Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alienor Berges

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
European Journal of Clinical Pharmacology|February 7, 2013
Dose finding by concentration-response versus dose-response: a simulation-based comparisonAlienor Berges, Chao Chen
Journal of Pharmacokinetics and Pharmacodynamics|January 12, 2015
Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theoryArmin Sepp, Alienor Berges, Andrew Sanderson, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult VolunteersAlienor Berges, Jonathan Robertson, James Upward, et al.
Clinical Therapeutics|July 20, 2010
Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteersAlienor Berges, Christine Walls, Shelly E Lener, et al.
Neuroimage|March 23, 2013
Non linear mixed effects analysis in PET PK-receptor occupancy studiesAlienor Berges, Vincent J Cunningham, Roger N Gunn, et al.
Plos One|February 24, 2015
Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsiesAlienor Berges, Jonathan Bullman, Stewart Bates, et al.
Clinical Pharmacology and Therapeutics|March 19, 2024
Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human HematopoiesisAnders Thorsted, Chiara Zecchin, Alienor Berges, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 13, 2019
Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and ratsArmin Sepp, Guy Meno-Tetang, Andrew Weber, et al.
Clinical Pharmacology and Therapeutics|January 20, 2026
Straight to Phase III: Model-Informed Approach Speeds Depemokimab Clinical Development in Interleukin-5-Driven DiseasesChiara Zecchin, Stein Schalkwijk, Isabelle J Pouliquen, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 23, 2018
Time-to-Event Modeling of Left- or Right-Censored Toxicity Data in Nonclinical Drug ToxicologyAlienor Berges, Marc Cerou, Tarjinder Sahota, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
European Journal of Clinical Pharmacology|February 7, 2013
Dose finding by concentration-response versus dose-response: a simulation-based comparisonAlienor Berges, Chao Chen
Journal of Pharmacokinetics and Pharmacodynamics|January 12, 2015
Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theoryArmin Sepp, Alienor Berges, Andrew Sanderson, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult VolunteersAlienor Berges, Jonathan Robertson, James Upward, et al.
Clinical Therapeutics|July 20, 2010
Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteersAlienor Berges, Christine Walls, Shelly E Lener, et al.
Neuroimage|March 23, 2013
Non linear mixed effects analysis in PET PK-receptor occupancy studiesAlienor Berges, Vincent J Cunningham, Roger N Gunn, et al.
Plos One|February 24, 2015
Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsiesAlienor Berges, Jonathan Bullman, Stewart Bates, et al.
Clinical Pharmacology and Therapeutics|March 19, 2024
Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human HematopoiesisAnders Thorsted, Chiara Zecchin, Alienor Berges, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 13, 2019
Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and ratsArmin Sepp, Guy Meno-Tetang, Andrew Weber, et al.
Clinical Pharmacology and Therapeutics|January 20, 2026
Straight to Phase III: Model-Informed Approach Speeds Depemokimab Clinical Development in Interleukin-5-Driven DiseasesChiara Zecchin, Stein Schalkwijk, Isabelle J Pouliquen, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 23, 2018
Time-to-Event Modeling of Left- or Right-Censored Toxicity Data in Nonclinical Drug ToxicologyAlienor Berges, Marc Cerou, Tarjinder Sahota, et al.
Pageof 2